Zussamenfassung
Wohl kaum ein in der Gynäkologie bedeutsames Hormon bereitet so häufig Probleme bei der Interpretation und ist daher ein möglicher Ausgangspunkt fragwürdiger diagnostischer und therapeutischer Entscheidungen wie Prolaktin. Nichtsdestotrotz kommt ihm im weiblichen Zyklus eine große Bedeutung zu. Unsicherheit besteht oft hinsichtlich der Notwendigkeit einer bildgebenden Diagnostik, dem Follow up auffälliger Werte, dem Verhalten bei Zyklusstörungen, bei Kinderwunsch, in der Schwangerschaft und Stillzeit. Diese Arbeit beschäftigt sich mit den genannten Punkten. Ihr Ziel ist: die Zusammenfassung der praxisrelevanten Kenntnisse und die Erarbeitung von Vorschlägen für mögliche Flussschemata in der Routine.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Riddle 0, Bates RW, Dykshorn SW (1933) The preparation, identification and assay of prolactin - a hormone of the anterior pituitary. Am J Physiol 105:191–216
Goffin V, Binart N, Touraine P, Kelly PA (2002) Prolactin. The new biology of an old hormone. Annu Rev Physiol 64:47–67
Goffin V, Shiverick KT, Kelly PA, Martial JA (1996) Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 17:385–410
Yazigi RA, Quintero CH, Salameh WA (1997) Prolactin disorders. Fertil Steril 67:215–225
Jacobs LS, Snyder PJ, Wilbur JF et al (1971) Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab 33:996–998
Clemens JA, Roush ME, Fuller RW (1978) Evidence that serotonin neurons stimulate secretion of prolactin releasing factor. Life Sci 22:2209221–3
Maslar IA, Riddick DH (1979) Prolactin production by human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 135:75175–4
Ben-Jonathan N, Mershon JL, Allen DL et al (1996) Extrapituitary prolactin: distribution, regulation and clinical aspects. Endocr Rev 17:639–669
McNatty KP, Sawers RS, McNeilly AS (1974) A possible role for prolactin in control of steroid secretion by the Graafian follicle. Nature 250:653–655
Phelps JY, Bugg EM, Shamblott MJ et al (2003) Prolactin gene expression in human ovarian follicular cells. Fertil Steril 79:182–185
Golander A, Hurley T, Barret J et al (1978) Prolactin synthesis by human chorion-decidual tissue: a possible source of prolactin in the amniotic fluid. Science 202:311–313
Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16:354–396
Posner B, Kelly PA, Shiu RP, Friesen HG (1974) Studies of insulin, growth hormone and prolactin binding: tissue distribution, species variation and characterization. Endocrinology 95:521–531
Arden KC, Boutin JM, Djiane J et al (1990) The receptors for prolactin and growth hormone are localized in the same region of human chromosome 5. Cytogenet Cell Genet 53:161–165
Astwood EB (1941) The regulation of corpus luteum function by hypophysial luteotrophin. Endocrinology 29:309–319
Bole-Feysot C, Goffin V, Edery M et al (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268
Raber W, Gessl A, Nowotny P, Vier- happer H (2003) Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization. Clin Endocrinol (Oxf) 58:18519–1
Schlechte J, Dolan K, Sherman B et al (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418
Verhelst J, Abs R (2003) Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2:23–32
Nawroth F (2005) Hyperprolactinemia and the regular menstrual cycle in asymptomatic women - should it be treated during therapy of infertility? Reprod Biomed Online 11:581–588
Velasquez EV, Trigo RV, Creus S et al (2006) Pituitary-ovarian axis during lactational amenorrhoea. I. Longitudinal assessment of follicular growth, gonadotrophins, sex steroids and inhibin levels before and after recovery of menstrual cyclicity. Hum Reprod 21:909–915
Velasquez EV, Creus S, Trigo RV et al (2006) Pituitary-ovarian axis during lactational amenorrhoea. II. Longitudinal assessment of serum FSH polymorphism before and after recovery of menstrual cycles. Hum Reprod 21:916–923
Naliato EC, Violante AH, Caldas D et al (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11:21–28
Vartej P, Poiana C, Vartej I (2001) Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 15:43–47
Ono M, Miki N, Amano K et al (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672–2679
Nawroth F, Ludwig M (2007) Persistierende Hyperprolaktinämie ohne Zyklusstörungen. Frauenarzt 48:454–459
Molitch ME, Russell EJ (1990) The pi- tuitary„incidentaloma". Ann Intern Med 112:925–931
Barlier A, Jaquet P (2006) Quinagolide - a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 154:187–195
Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38
Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:394–6
Tan T, Cabrita IZ, Hensman D et al (2010) Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 73:369–374
Auriemma RS, Pivonello R, Perone Y et al (2013) Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 169:35936–6
Dekkers OM, Lagro J, Burman P et al (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43–51
Colao A, Di Sarno A, Cappabianca P et al (2003) Withdrawal of long-term cabergoline therapy for tu moral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033
Auriemma RS, Perone Y, Di Sarno A et al (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98:372–379
Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Nawroth, F. (2017). Hyperprolaktinämie. In: Dimpfl, T., et al. Weiterbildung Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49480-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-49480-6_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49479-0
Online ISBN: 978-3-662-49480-6
eBook Packages: Medicine (German Language)